These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3223134)

  • 21. Comparative in vitro activity of RO 23-6240 (fleroxacin), a new 4-quinolone derivative.
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Aug; 6(4):482-5. PubMed ID: 3117538
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR; Cobbs CG
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of RO 23-6240 (AM-833): a new fluoroquinolone.
    Fass RJ; Helsel VL
    Diagn Microbiol Infect Dis; 1987 Apr; 6(4):293-9. PubMed ID: 3107872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
    Kowalski RP; Dhaliwal DK; Karenchak LM; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2003 Sep; 136(3):500-5. PubMed ID: 12967804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of levofloxacin and ciprofloxacin against urinary pathogens.
    Drago L; De Vecchi E; Mombelli B; Nicola L; Valli M; Gismondo MR
    J Antimicrob Chemother; 2001 Jul; 48(1):37-45. PubMed ID: 11418511
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
    Kumada T; Neu HC
    J Antimicrob Chemother; 1985 Nov; 16(5):563-74. PubMed ID: 3865923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates.
    Becnel Boyd L; Maynard MJ; Morgan-Linnell SK; Horton LB; Sucgang R; Hamill RJ; Jimenez JR; Versalovic J; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):229-34. PubMed ID: 18838594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.
    Kern W; Gulden H; Vanek E; Kurrle E
    Chemotherapy; 1988; 34(2):117-26. PubMed ID: 3164670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in vitro activity of norfloxacin, ofloxacin and ciprofloxacin and other antibiotics in current use against Neisseria gonorrhoeae.
    Melby K; Faegri A
    APMIS; 1989 Apr; 97(4):347-50. PubMed ID: 2497756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A
    Scand J Infect Dis; 1985; 17(1):91-4. PubMed ID: 3158070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative in vitro bacteriostatic and bactericidal activity of levofloxacin and ciprofloxacin against urinary tract pathogens determined by MIC, MBC, Time-Kill curves and bactericidal index analysis].
    Noviello S; Ianniello F; Leone S; Esposito S
    Infez Med; 2002 Jun; 10(2):100-6. PubMed ID: 12702887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Penetration of ciprofloxacin, norfloxacin and ofloxacin into the aqueous humor using different topical application modes.
    Beck R; van Keyserlingk J; Fischer U; Guthoff R; Drewelow B
    Graefes Arch Clin Exp Ophthalmol; 1999 Feb; 237(2):89-92. PubMed ID: 9987622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of ciprofloxacin, norfloxacin, and ofloxacin against multi-resistant Enterobacteriaceae.
    Niculescu E; Wagener H
    Chemioterapia; 1987 Jun; 6(2 Suppl):132-3. PubMed ID: 3509369
    [No Abstract]   [Full Text] [Related]  

  • 36. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin.
    Fujimoto T; Mitsuhashi S
    Chemotherapy; 1990; 36(4):268-76. PubMed ID: 2174762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibacterial activity of ofloxacin and its mode of action.
    Sato K; Inoue Y; Fujii T; Aoyama H; Mitsuhashi S
    Infection; 1986; 14 Suppl 4():S226-30. PubMed ID: 3028966
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates.
    López-Brea M; Prieto N; Domingo D; de las Cuevas C; Sánchez I; Alarcón T
    Int J Antimicrob Agents; 1999 Jun; 12(1):33-9. PubMed ID: 10389645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.